Trial Profile
A Randomized, Double-blind, Placebo-controlled Study in Healthy Volunteers to Examine the Safety, Tolerability and Pharmacokinetics of a) Single, Ascending and b) Twice-daily Repeat Doses of Intranasal SB-705498
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Oct 2023
Price :
$35
*
At a glance
- Drugs GSK 705498 (Primary)
- Indications Rhinitis
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline; GSK
- 05 Aug 2013 Results published in the British Journal of Clinical Pharmacology.
- 12 Dec 2009 New trial record